Data on bone metabolism in individuals lacking AVP release-and possibly also oxytocin-such as patients with AVP deficiency (AVP-D, also known as central diabetes insipidus) remain scarce, although the limited available evidence suggests a potentially deleterious effect.<h4>Objective</h4>This study aimed to evaluate bone turnover markers in patients with AVP-D compared to individuals with primary polydipsia (PP) and healthy controls (HC).<h4>Methods</h4>This was a secondary analysis of the prospective URANOS Trial (NCT05890690) conducted from June 2023 to June 2024. This evidence concerns the gene OXT and neurohypophyseal diabetes insipidus.